PLUR (Pluri) Short-Term Debt to Capital

Corporate company logo of Pluristem Therapeutics (PLUR)

Pluri Inc. (PLUR) specializes in the industrial creation of cellular structures using 3D technologies for medicine and nutrition. The price history on GURU.Markets shows the indicator 0.00. The business relies on ESG principles when operating bioreactors and adheres to strict bioethics. To reduce costs, Pluri Inc. (PLUR) delegates the final stages of drug testing to external partners while maintaining its leadership in cultivation.

Ratio of Short-Term Indebtedness to Capital: pluri-biotech.com (PLUR) for 04/28/2023 - 10/30/2026

Analytical breakdowns for Pluri Inc.

- stock quotes and analyst forecast:
Stock Price Pluri Inc.|PLUR - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Pluristem Therapeutics|PLUR - Enterprise Value
- book capitalization information:
Net Assets per Single Share Pluri|PLUR - Accounting Value of Company|Market Value to Book Value Ratio pluri-biotech.com|PLUR - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Pluri Inc.|PLUR - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Pluri Inc.|PLUR - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Pluristem Therapeutics|PLUR - Company Long-Term Liabilities|Company Short-Term Debts Pluri|Quick Liquidity Indicator pluri-biotech.com
- company profitability and valuation multiples indicators:
PLUR - Profit After Payment of Taxes
Fundamental valuation:PLUR Pluri
Brand item of pluri-biotech.com

A comparative asset analysis requires a liquidity assessment via the ratio of liabilities under one year to equity, where the value of 0.00 determines the level of financial pressure on the business. For Pluri Inc. (PLUR), this proportion of short-term debt to equity is critical, as the costs of scaling cell lines and clinical therapy trials directly impact default risk or resource efficiency.

Competitors of Pluri Inc.

Short-Term Debt to Capital ASND|MDGL (Madrigal Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CORT (Corcept Therapeutics)|Short-Term Debt to Capital rhythmtx.com RYTM|AKRO - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MTSR (Metsera, Inc.)|MoonLake Pharma (MLTX) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Crinetics Corp|NAMS (NewAmsterdam Pharma) - Short-Term Debt to Capital|Short-Term Debt to Capital soleno.life|Short-Term Debt to Equity Ratio FOLD (Amicus Therapeutics, Inc.)|ETNB (89bio Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Agios Pharmaceuticals Inc AGIO|GPCR - Short-Term Debt to Equity Ratio|MiMedx Group, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital rezolutebio.com|LXRX (Lexicon Pharmaceuticals, Inc.) - Short-Term Debt to Equity Ratio|MBX: Short-Term Loans to Capital Ratio|ALT (Altimmune Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital Aardvark Pharma|Short-Term Debt to Capital SGMT|Short-Term Debt to Equity BIOA (bioagelabs.com)|Short-Term Debt to Equity Biomea Fusion BMEA|Quince Therapeutics Inc (QNCX) - Current Liabilities to Capital|GUTS - Short-Term Debt to Equity|VTVT: Short-Term Debt to Equity|ATPC: Short-Term Debt to Capital|SYBX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lipocine|Matinas BioPharma Holdings Inc. (MTNB) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Spruce Biosciences (SPRB)|Short-Term Debt to Equity Ratio Galecto Corporation GLTO|Short-Term Debt to Equity Carmell Corporation CTCX|LUMO (lumos-pharma.com) - Current Liabilities to Equity|ONVO - Short-Term Debt to Equity|RDUS: Short-Term Debt to Equity